A method, system and electronic device for identifying drug-resistant genes

Through drug resistance analysis and correction based on drug resistance gene database, the problem of high accuracy and cost of drug resistance gene detection in the prior art has been solved, and a wider and more accurate drug resistance gene detection has been achieved, supporting clinical personalized treatments .

CN114283886BActive Publication Date: 2024-12-03CAPITALBIO CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111582436.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-12-22
Publication Date
2024-12-03
Estimated Expiration
2041-12-22

AI Technical Summary

Technical Problem

Existing drug-resistant gene detection methods such as qPCR detection methods are costly, complex in operation and easy to introduce errors, resulting in reduced detection accuracy and making it difficult to detect multiple drug-resistant genes at the same time.

Method used

By obtaining the target sample to be detected, drug resistance analysis is performed based on the target drug resistance gene database, homologous and SNP-type drug resistance gene data are integrated, sequence comparison and annotation are performed, target drug resistance gene database is generated, and clinical data is corrected. , improve the accuracy of the test results.

Benefits of technology

The scope of drug resistance detection has been expanded, the integrity and accuracy of the detection has been improved, reliable clinical test results can be provided, and the changes in drug resistance genes can be monitored and treatment plans can be adjusted.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114283886B_ABST
    Figure CN114283886B_ABST
Patent Text Reader

Abstract

The present invention discloses a method, system and electronic device for identifying drug resistance genes, including: obtaining a target sample to be detected; performing drug resistance analysis on the target sample to be detected based on a target drug resistance gene database to obtain an initial drug resistance analysis result, wherein the target drug resistance gene database includes homologous drug resistance gene sequences and single nucleotide polymorphism (SNP) drug resistance gene data; correcting the initial drug resistance analysis result to obtain a target drug resistance detection result. The detection objects of the present invention include drug resistance genes based on homologous genotypes and drug resistance genes based on SNP typing, which expands the scope of drug resistance detection, and can correct drug resistance analysis results, thereby improving the integrity and accuracy of drug resistance detection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of microbial detection, and in particular to a drug-resistant gene identification method, system and electronic equipment. Background Art

[0002] Antibiotics are the most widely used antimicrobial drugs in clinical practice. With the widespread use of antimicrobial drugs, drug-resistant bacteria continue to emerge, and the monitoring of different types of drug-resistant genes has become a research focus. Currently, the existing bacterial resistance detection methods can be divided into two categories: classical methods and bacterial drug sensitivity detection and new drug resistance detection technologies.

[0003] New technologies for drug resistance detection mainly include PCR (Polymerase Chain Reaction) detection method and mass spectrometry detection method. Among them, qPCR (Quantitative Real-time PCR) detection method is similar to the present invention. Before qPCR detection of drug-resistant genes, it is first necessary to determine the specific drug-resistant genes to be detected, design qPCR primers and select internal reference genes. After extracting the sample DNA, a subsequent qPCR reaction is performed to determine whether the drug-resistant gene exists. However, a qPCR reaction can generally only detect one drug-resistant gene, because there are many types of drug-resistant genes, and usually hundreds of drug-resistant genes need to be detected at the same time, and the qPCR detection cost of a large number of samples is high, the operation process is complicated, and it is easy to introduce operational errors, thereby reducing the accuracy of drug-resistant gene detection. Summary of the invention

[0004] In view of the above problems, the present invention provides a method, system and electronic equipment for identifying drug-resistant genes, which improve the accuracy of drug-resistant gene detection and provide reliable detection results for clinicians.

[0005] In order to achieve the above object, the present invention provides the following technical solutions:

[0006] A method for identifying drug resistance genes, comprising:

[0007] Obtain the target sample to be tested;

[0008] Performing drug resistance analysis on the target sample to be tested based on a target drug resistance gene database to obtain an initial drug resistance analysis result, wherein the target drug resistance gene database includes homologous drug resistance gene sequences and single nucleotide polymorphism (SNP) drug resistance gene data;

[0009] The initial drug resistance analysis result is corrected to obtain a target drug resistance detection result.

[0010] Optionally, obtaining a target sample to be detected includes:

[0011] Obtaining the original sequencing sequence of the target to be detected;

[0012] The original sequencing sequence is quality controlled to obtain a target sample to be tested, wherein the quality control at least includes filtering low-quality sequences, cutting off low-quality bases at both ends of the sequence, and removing plasmid sequences and host genome sequences that are not related to drug-resistant genes.

[0013] Optionally, the method further comprises:

[0014] Obtaining a drug-resistant gene sequence from a multidimensional source database, wherein the drug-resistant gene sequence includes a homologous drug-resistant gene sequence and a single nucleotide polymorphism (SNP) drug-resistant gene sequence;

[0015] Integrating the drug-resistant gene sequences to remove redundant drug-resistant gene sequences and obtain a first processing result, wherein removing the drug-resistant gene sequences includes retaining a target base sequence;

[0016] Classifying the first processing result according to the drug resistance gene family as a unit to obtain a second processing result;

[0017] Classifying the second processing result based on the drug resistance gene function and annotation information, and annotating the corresponding biological function and source microbial information to obtain a third processing result;

[0018] Performing similarity analysis on different drug-resistant gene family sequences in the third processing result, and performing processing based on the similarity analysis result to obtain target drug-resistant gene sequence information;

[0019] Based on the target drug resistance gene sequence information, a target drug resistance gene database is generated.

[0020] Optionally, the annotation information in the target drug-resistant gene database includes: gene name, gene family name, source database, drug-resistant gene type, drug-resistant mechanism, description information, species source information, whether SNP verification is required, SNP name, SNP mutation information and literature identification source information.

[0021] Optionally, the correcting the initial drug resistance analysis result to obtain a target drug resistance detection result includes:

[0022] Obtain clinical data of a target subject corresponding to the target sample to be tested;

[0023] Obtain target resistance monitoring data;

[0024] Based on the clinical data of the target subject and the target drug resistance monitoring data, the initial drug resistance analysis result is corrected to obtain the target drug resistance detection result.

[0025] A drug resistance gene identification system, comprising:

[0026] An acquisition unit, used for acquiring a target sample to be detected;

[0027] An analysis unit, configured to perform drug resistance analysis on the target sample to be detected based on a target drug resistance gene database to obtain an initial drug resistance analysis result, wherein the target drug resistance gene database includes homologous drug resistance gene sequences and single nucleotide polymorphism (SNP) drug resistance gene data;

[0028] The correction unit is used to correct the initial drug resistance analysis result to obtain a target drug resistance detection result.

[0029] Optionally, the acquiring unit includes:

[0030] A first acquisition subunit is used to acquire the original sequencing sequence of the target to be detected;

[0031] The quality control subunit is used to perform quality control on the original sequencing sequence to obtain the target sample to be tested, wherein the quality control at least includes filtering low-quality sequences, cutting off low-quality bases at both ends of the sequence, and removing plasmid sequences and host genome sequences that are not related to drug-resistant genes.

[0032] Optionally, the system further comprises: a database establishing unit, wherein the database establishing unit is specifically used for:

[0033] Obtaining a drug-resistant gene sequence from a multidimensional source database, wherein the drug-resistant gene sequence includes a homologous drug-resistant gene sequence and a single nucleotide polymorphism (SNP) drug-resistant gene sequence;

[0034] Integrating the drug-resistant gene sequences to remove redundant drug-resistant gene sequences and obtain a first processing result, wherein removing the drug-resistant gene sequences includes retaining a target base sequence;

[0035] Classifying the first processing result according to the drug resistance gene family as a unit to obtain a second processing result;

[0036] Classifying the second processing result based on the drug resistance gene function and annotation information, and annotating the corresponding biological function and source microbial information to obtain a third processing result;

[0037] Performing similarity analysis on different drug-resistant gene family sequences in the third processing result, and performing processing based on the similarity analysis result to obtain target drug-resistant gene sequence information;

[0038] Based on the target drug resistance gene sequence information, a target drug resistance gene database is generated.

[0039] Optionally, the correction unit includes:

[0040] The second acquisition subunit is used to acquire clinical data of a target subject corresponding to the target sample to be tested;

[0041] The third acquisition subunit is used to obtain target drug resistance monitoring data;

[0042] The correction subunit is used to correct the initial drug resistance analysis result based on the clinical data of the target subject and the target drug resistance monitoring data to obtain the target drug resistance detection result.

[0043] An electronic device, comprising:

[0044] Memory, used to store programs;

[0045] The processor is used to execute the program, and the program is specifically used to implement a method for identifying drug-resistant genes as described above.

[0046] Compared with the prior art, the present invention provides a method, system and electronic device for identifying drug resistance genes, including: obtaining a target sample to be detected; performing drug resistance analysis on the target sample to be detected based on a target drug resistance gene database to obtain an initial drug resistance analysis result, wherein the target drug resistance gene database includes homologous drug resistance gene sequences and single nucleotide polymorphism (SNP) drug resistance gene data; correcting the initial drug resistance analysis result to obtain a target drug resistance detection result. The detection objects of the present invention include drug resistance genes based on homologous genotypes and drug resistance genes based on SNP typing, which expands the scope of drug resistance detection, and can correct drug resistance analysis results, thereby improving the integrity and accuracy of drug resistance detection. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0048] Figure 1 A schematic diagram of a process for identifying drug-resistant genes provided by an embodiment of the present invention;

[0049] Figure 2 A schematic diagram of the structure of a drug resistance gene identification system provided in an embodiment of the present invention. DETAILED DESCRIPTION

[0050] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0051] The terms "first" and "second" and the like in the specification and claims of the present invention and the above drawings are used to distinguish different objects, rather than to describe a specific order. In addition, the terms "including" and "having" and any variations thereof are intended to cover non-exclusive inclusions. For example, a process, method, system, product or device including a series of steps or units is not limited to the listed steps or units, but may include steps or units that are not listed.

[0052] In an embodiment of the present invention, a method for identifying drug-resistant genes is provided, which is mainly used for drug-resistant gene detection and analysis on gene panel capture sequencing, second-generation sequencing and third-generation sequencing platforms. Sequence comparison analysis and drug-resistant gene annotation can be performed based on the target drug-resistant gene database, and the initial drug-resistant analysis results can be corrected, thereby improving the accuracy of drug-resistant gene detection and providing reliable detection results for clinical practice.

[0053] See also Figure 1 , is a schematic diagram of a process for identifying a drug-resistant gene provided by an embodiment of the present invention, the method may include the following steps:

[0054] S101, obtaining a target sample to be detected.

[0055] The target sample to be detected refers to a sample that needs to be identified for drug-resistant genes, which can specifically be the original sequencing sequence of the target to be detected, and the target to be detected can be a patient in the clinic. In the embodiment of the present invention, it can be compatible with and receive sequencing sequences from macrogenes or high-throughput sequencing sequences of drug-resistant genes, and support second-generation sequencing platforms or third-generation sequencing platforms. For ease of explanation, the high-throughput sequencing data in the embodiment of the present invention comes from the second-generation sequencing platform. After obtaining the original sequencing sequence of the target to be detected, in order to improve the accuracy of subsequent identification, the sequencing sequence quality control can be performed on the pathogen high-throughput sequencing data, and low-quality sequences are filtered in turn, low-quality bases at both ends of the sequence are cut off, and plasmid sequences and host genome sequences that are not related to drug-resistant genes are removed.

[0056] It should be noted that the present invention also supports other forms such as panel targeted capture of high-throughput sequencing data. All target drug-resistant genes can be integrated together through panel targeted multi-gene sequencing. The panel capture sequencing technology can greatly improve the sequencing depth of the drug-resistant gene region, improve the detection accuracy, and at the same time improve the reliability of drug-resistant gene annotation.

[0057] S102, performing drug resistance analysis on the target sample to be detected based on the target drug resistance gene database to obtain an initial drug resistance analysis result.

[0058] Among them, in the embodiment of the present invention, drug resistance gene data is constructed based on the drug resistance gene nucleic acid sequence information to obtain a target drug resistance gene database. Further, the target drug resistance gene database includes homologous drug resistance gene sequences and single nucleotide polymorphism SNP type drug resistance gene data. Based on sequence alignment and mutation analysis, two different drug resistance genes, homologous resistance and SNP resistance, can be respectively targeted to improve the integrity and accuracy of drug resistance detection.

[0059] BLAST is used to compare the high-quality sequencing sequence after quality control with the target drug resistance gene database. For SNP-type drug resistance genes, SNP analysis is performed separately to determine whether the SNP type is consistent with the known drug resistance SNP contained in the SNP drug resistance gene database. The drug resistance gene is quantified and annotated with function, source and drug information to obtain the initial drug resistance analysis results of the target sample to be tested.

[0060] S103, correcting the initial drug resistance analysis result to obtain a target drug resistance detection result.

[0061] In one embodiment of the present invention, the correction of the initial drug resistance analysis result to obtain the target drug resistance detection result may include: obtaining clinical data of the target object corresponding to the target sample to be detected; obtaining target drug resistance monitoring data; based on the clinical data of the target object and the target drug resistance monitoring data, correcting the initial drug resistance analysis result to obtain the target drug resistance detection result.

[0062] Among them, the target drug resistance monitoring data refers to the prevalence data of drug-resistant genes in the country, and the clinical data of the target objects are relevant data obtained by monitoring the drug resistance of long-term bedridden infected patients in combination with clinical related information.

[0063] Specifically, according to clinical treatment, especially feedback on antibiotic use, comprehensive consideration of drug resistance monitoring data in various regions, drug resistance analysis results are filtered and corrected to improve detection reliability. Especially for immunocompromised patients or elderly patients with lung infections, the course of the disease is generally long, the infection is complex, and there are multiple pathogens. In the long-term hospitalization of such patients, this system can be combined with clinical treatment feedback information to monitor changes in drug resistance genes during the patient's treatment, assist clinicians in adjusting treatment plans at any time, improve treatment effectiveness and accuracy, and achieve accurate diagnosis and personalized drug treatment.

[0064] The present invention provides a method for identifying drug-resistant genes based on high-throughput sequencing data of drug-resistant genes (antimicrobial resistance NGS, amrNGS) or other targeted capture sequencing data, and constructs an accurate and comprehensive database of target drug-resistant genes to perform sequencing data quality control, sequence alignment, drug-resistant gene quantification and gene annotation. Then, combined with clinical treatment, especially feedback on antibiotic use, comprehensive consideration of drug-resistant monitoring data in various regions, drug-resistant analysis results are filtered and corrected to improve detection reliability.

[0065] In one implementation of the embodiment of the present invention, a method for establishing a target drug resistance gene database is also provided, and the method may include the following steps:

[0066] S201. Obtain drug-resistant gene sequences from a multidimensional source database, wherein the drug-resistant gene sequences include homologous drug-resistant gene sequences and single nucleotide polymorphism (SNP) drug-resistant gene sequences.

[0067] S202, integrating the drug-resistant gene sequences to remove redundant drug-resistant gene sequences and obtain a first processing result, wherein removing the drug-resistant gene sequences includes retaining a target base sequence.

[0068] S203, classifying the first processing result according to drug-resistant gene families to obtain a second processing result.

[0069] S204: Classify the second processing result based on the drug-resistant gene function and annotation information, and annotate the corresponding biological function and source microorganism information to obtain a third processing result.

[0070] S204, performing similarity analysis on different drug-resistant gene family sequences in the third processing result, and performing processing based on the similarity analysis result to obtain target drug-resistant gene sequence information.

[0071] S205. Generate a target drug-resistance gene database based on the target drug-resistance gene sequence information.

[0072] It should be noted that when creating a target drug-resistant gene database in an embodiment of the present invention, the first processing result, the second processing result, and the third processing result obtained are all intermediate processing results of the relevant data when establishing the database. They are only for distinguishing the results in different processing flows and do not have a specific order. The above-mentioned steps can be reasonably adjusted in sequence, and the present invention does not limit the specific processing order.

[0073] Specifically, in order to ensure the comprehensiveness and accuracy of the target drug-resistant gene database data created, drug-resistant gene sequences from multi-source databases will be collected in the embodiment of the present invention. Multi-source refers to different sources, and specifically can be from different public databases. For example, 4577 homologous drug-resistant gene sequences and 247 SNP mutant drug-resistant gene sequences were downloaded from the CARD database (https: / / card.mcmaster.ca). A total of 10252 drug-resistant gene sequences were downloaded from the NCBI database (https: / / ncbi.nlm.nih.gov). A total of 7126 drug-resistant gene sequences were obtained from the MEGARes database (http: / / megares.meglab.org / ). After obtaining the relevant drug-resistant gene sequences, relevant processing such as integration, classification, and annotation can be performed to obtain relevant information that can be used as a drug-resistant gene database. Specifically, all drug-resistant gene sequences can be integrated according to the 100% similarity threshold, redundant drug-resistant gene sequences can be removed, and sequences with more bases and higher lengths can be retained during the removal of redundant sequences. Taking the drug-resistant gene family as a unit, the drug-resistant gene sequence is sorted and classified according to the drug-resistant gene function and annotation information, and different biological functions, source microorganisms and other information are marked. FastANI is used to perform similarity analysis on the sequences of different drug-resistant gene families, sort out the same drug-resistant gene sequences, remove similar gene sequences with a similarity of more than 99%, and filter and correct the gene sequences involved in all gene families to unify the gene naming. Since the drug resistance detection method caused by SNP mutation is different from that of other drug-resistant genes, the present invention separately constructs a SNP drug-resistant gene database and improves the annotation information. The annotation information in the drug-resistant gene database includes gene name, gene family name, source database, drug-resistant gene type, drug-resistant gene classification, drug resistance mechanism, description information, species source information, whether SNP verification is needed, SNP name, SNP mutation information, PubMed document ID source, etc.

[0074] The following describes the drug resistance gene identification method of the embodiment of the present invention by taking a specific clinical application scenario as an example.

[0075] In one embodiment, for a patient with clinically critical pneumonia, the mNGS test results showed that the patient was infected with Mycoplasma pneumoniae. First, the sample was subjected to drug resistance gene analysis and found that the sample had a macrolide resistance mutation, which was an A2063G mutation of the 23rRNA gene of Mycoplasma pneumoniae.

[0076] Combined with the clinical medication situation, it was found that the patient had used azithromycin in the past 3 days and had no significant improvement. It was confirmed that the patient carried the macrolide resistance gene of Mycoplasma pneumoniae and had resistance to antibiotics such as erythromycin and azithromycin. In the patient's clinical laboratory examination, based on the patient's bronchoalveolar lavage fluid (BALF) sample, Mycoplasma pneumoniae was first isolated and cultured, and then the resistance was determined. At the same time, the resistance of 6 antibiotics including macrolides, tetracyclines and quinolones was detected. Based on the standard minimum inhibitory concentration (MIC) method, the resistance of Mycoplasma pneumoniae carried by the patient to the above antibiotics was detected respectively. The resistance concentration threshold of macrolides is MIC ≥ 1.0ug / ml, the resistance concentration threshold of tetracyclines is MIC ≥ 2.0ug / ml, and the resistance concentration threshold of quinolones is MIC ≥ 1.0ug / ml. The standard strain of Mycoplasma pneumoniae M129 (ATCC29342) was used as a control for drug sensitivity experiments. The results of drug sensitivity test showed that the MIC90 concentration of Mycoplasma pneumoniae carried by the patient against erythromycin was 1024ug / ml, and the MIC90 concentration against azithromycin was 128ug / ml, indicating that the patient had obvious drug resistance. To verify the existence of the A2063G mutation in the 23S rRNA gene of Mycoplasma pneumoniae, we used the forward 5'-3' primer TAACTATAACGGTCCTAAGG and the reverse 5'-3' primer CGCTACAACTGGAGCATAAGA to perform targeted amplification on the DNA extracted from Mycoplasma pneumoniae. The amplification conditions were an initial temperature of 95℃ for 2min, followed by 30 PCR cycles (95℃ for 30sec, 55℃ for 30sec, 72℃ for 30sec), and finally 72℃ for 2min. Finally, the amplified product was purified, the library was constructed, and the sequencing was performed on the machine. The sequenced sequence was compared with the Mycoplasma pneumoniae 23S rRNA gene sequence using blast to confirm the existence of the A2063G mutation in the 23r RNA gene.

[0077] The present invention does not require bacterial culture and purification, saving a lot of time. It can also be used for drug resistance gene detection of some uncultivable or difficult-to-cultivate bacteria, expanding the detection range. In addition, it is not necessary to design drug resistance gene-related primers in advance, so the extraction method is simple. It can also be combined with clinically relevant information and mutually verified with drug resistance detection to make the identification results reliable. In addition, the drug resistance of long-term bedridden infected patients can be monitored, assisting clinicians to adjust treatment plans at any time and realize personalized diagnosis and treatment.

[0078] The high-throughput sequencing platform of the present invention is not limited, and can be a second-generation sequencing platform or a third-generation sequencing platform, including Illumina, Ion torrent, BGI, SMRT or Nanopore sequencing platforms. The homologous drug resistance and SNP drug resistance can be analyzed separately, and the drug resistance detection results can be filtered and corrected using clinical treatment information and drug resistance epidemic information, thereby further improving the detection reliability.

[0079] In another embodiment of the present invention, a drug resistance gene identification system is provided. Figure 2 , the system may include:

[0080] An acquisition unit 301 is used to acquire a target sample to be detected;

[0081] The analysis unit 302 is used to perform drug resistance analysis on the target sample to be detected based on the target drug resistance gene database to obtain an initial drug resistance analysis result, wherein the target drug resistance gene database includes homologous drug resistance gene sequences and single nucleotide polymorphism (SNP) drug resistance gene data;

[0082] The correction unit 303 is used to correct the initial drug resistance analysis result to obtain a target drug resistance detection result.

[0083] In one embodiment, the acquisition unit includes:

[0084] A first acquisition subunit is used to acquire the original sequencing sequence of the target to be detected;

[0085] The quality control subunit is used to perform quality control on the original sequencing sequence to obtain the target sample to be tested, wherein the quality control at least includes filtering low-quality sequences, cutting off low-quality bases at both ends of the sequence, and removing plasmid sequences and host genome sequences that are not related to drug-resistant genes.

[0086] In another embodiment, the system further includes: a database establishment unit, wherein the database establishment unit is specifically used to:

[0087] Obtaining a drug-resistant gene sequence from a multidimensional source database, wherein the drug-resistant gene sequence includes a homologous drug-resistant gene sequence and a single nucleotide polymorphism (SNP) drug-resistant gene sequence;

[0088] Integrating the drug-resistant gene sequences to remove redundant drug-resistant gene sequences and obtain a first processing result, wherein removing the drug-resistant gene sequences includes retaining a target base sequence;

[0089] Classifying the first processing result according to the drug resistance gene family as a unit to obtain a second processing result;

[0090] Classifying the second processing result based on the drug resistance gene function and annotation information, and annotating the corresponding biological function and source microbial information to obtain a third processing result;

[0091] Performing similarity analysis on different drug-resistant gene family sequences in the third processing result, and performing processing based on the similarity analysis result to obtain target drug-resistant gene sequence information;

[0092] Based on the target drug-resistance gene sequence information, a target drug-resistance gene database is generated.

[0093] Furthermore, the annotation information in the target drug-resistant gene database includes: gene name, gene family name, source database, drug-resistant gene type, drug-resistant mechanism, description information, species source information, whether SNP verification is required, SNP name, SNP mutation information and literature identification source information.

[0094] Optionally, the correction unit includes:

[0095] The second acquisition subunit is used to acquire clinical data of the target subject corresponding to the target sample to be tested;

[0096] The third acquisition subunit is used to obtain target drug resistance monitoring data;

[0097] The correction subunit is used to correct the initial drug resistance analysis result based on the clinical data of the target subject and the target drug resistance monitoring data to obtain the target drug resistance detection result.

[0098] The embodiment of the present invention provides a drug resistance gene identification system, comprising: an acquisition unit acquires a target sample to be detected; an analysis unit performs drug resistance analysis on the target sample to be detected based on a target drug resistance gene database to obtain an initial drug resistance analysis result, wherein the target drug resistance gene database includes homologous drug resistance gene sequences and single nucleotide polymorphism (SNP) drug resistance gene data; a correction unit corrects the initial drug resistance analysis result to obtain a target drug resistance detection result. The detection objects of the present invention include drug resistance genes based on homologous genotypes and drug resistance genes based on SNP typing, which expands the scope of drug resistance detection, and can correct drug resistance analysis results, thereby improving the integrity and accuracy of drug resistance detection.

[0099] Based on the aforementioned embodiments, embodiments of the present application provide a computer-readable storage medium, which stores one or more programs, and the one or more programs can be executed by one or more processors to implement the steps of any of the above methods for identifying drug-resistant genes.

[0100] An embodiment of the present invention further provides an electronic device, the electronic device comprising:

[0101] Memory, used to store programs;

[0102] The processor is used to execute the program, and the program is specifically used to implement a method for identifying drug-resistant genes as described above.

[0103] It should be noted that the processor or CPU may be at least one of an Application Specific Integrated Circuit (ASIC), a Digital Signal Processor (DSP), a Digital Signal Processing Device (DSPD), a Programmable Logic Device (PLD), a Field Programmable Gate Array (FPGA), a Central Processing Unit (CPU), a controller, a microcontroller, and a microprocessor. It is understandable that the electronic device that implements the above-mentioned processor function may also be other, and the embodiments of the present application are not specifically limited.

[0104] It should be noted that the above-mentioned computer storage medium / memory can be a read-only memory (ROM), a programmable read-only memory (PROM), an erasable programmable read-only memory (EPROM), an electrically erasable programmable read-only memory (EEPROM), a magnetic random access memory (FRAM), a flash memory (Flash Memory), a magnetic surface memory, an optical disc, or a compact disc read-only memory (CD-ROM) and other memories; it can also be various terminals including one or any combination of the above-mentioned memories, such as mobile phones, computers, tablet devices, personal digital assistants, etc.

[0105] In the several embodiments provided in the present application, it should be understood that the disclosed devices and methods can be implemented in other ways. The device embodiments described above are only schematic. For example, the division of the units is only a logical function division. There may be other division methods in actual implementation, such as: multiple units or components can be combined, or can be integrated into another system, or some features can be ignored or not executed. In addition, the coupling, direct coupling, or communication connection between the components shown or discussed can be through some interfaces, and the indirect coupling or communication connection of the devices or units can be electrical, mechanical or other forms.

[0106] The units described above as separate components may or may not be physically separated, and the components displayed as units may or may not be physical units, that is, they may be located in one place or distributed on multiple network units; some or all of the units may be selected according to actual needs to achieve the purpose of the scheme of this embodiment.

[0107] In addition, all functional units in the embodiments of the present application can be integrated into one processing module, or each unit can be a separate unit, or two or more units can be integrated into one unit; the above integrated unit can be implemented in the form of hardware or in the form of hardware plus software functional units. A person of ordinary skill in the art can understand that all or part of the steps of implementing the above method embodiments can be completed by hardware related to program instructions, and the aforementioned program can be stored in a computer-readable storage medium, which, when executed, executes the steps of the above method embodiments; and the aforementioned storage medium includes: mobile storage devices, read-only memory (ROM), random access memory (RAM), disks or optical disks, and other media that can store program codes.

[0108] The methods disclosed in several method embodiments provided in this application can be arbitrarily combined without conflict to obtain new method embodiments.

[0109] The features disclosed in several product embodiments provided in this application can be arbitrarily combined without conflict to obtain new product embodiments.

[0110] The features disclosed in several method or device embodiments provided in this application can be arbitrarily combined without conflict to obtain new method embodiments or device embodiments.

[0111] The above is only a specific implementation of the present application, but the protection scope of the present application is not limited thereto. Any person skilled in the art who is familiar with the present technical field can easily think of changes or substitutions within the technical scope disclosed in the present application, which should be included in the protection scope of the present application. Therefore, the protection scope of the present application should be based on the protection scope of the claims.

[0112] In this specification, each embodiment is described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the embodiments can be referred to each other. For the device disclosed in the embodiment, since it corresponds to the method disclosed in the embodiment, the description is relatively simple, and the relevant parts can be referred to the method part.

[0113] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A method for identifying drug resistance genes, It is characterized in that include: Obtaining a target sample to be detected, including: obtaining an original sequencing sequence of the target to be detected; performing quality control on the original sequencing sequence to obtain a target sample to be detected, wherein the quality control at least includes filtering low-quality sequences, removing low-quality bases at both ends of the sequence, and removing plasmid sequences and host genome sequences that are not related to drug-resistant genes; Performing drug resistance analysis on the target sample to be tested based on a target drug resistance gene database to obtain an initial drug resistance analysis result, wherein the target drug resistance gene database includes homologous drug resistance gene sequences and single nucleotide polymorphism (SNP) drug resistance gene data; Correcting the initial drug resistance analysis result to obtain a target drug resistance detection result, including: obtaining clinical data of a target subject corresponding to a target sample to be detected; obtaining target drug resistance monitoring data; correcting the initial drug resistance analysis result based on the clinical data of the target subject and the target drug resistance monitoring data to obtain a target drug resistance detection result; The method further comprises: Obtaining drug-resistant gene sequences from a multidimensional source database, wherein the drug-resistant gene sequences include homologous drug-resistant gene sequences and single nucleotide polymorphism (SNP) drug-resistant gene sequences; multidimensional sources refer to different sources; Integrating the drug-resistant gene sequences to remove redundant drug-resistant gene sequences and obtain a first processing result, wherein removing the drug-resistant gene sequences includes retaining a target base sequence; Classifying the first processing result according to the drug resistance gene family as a unit to obtain a second processing result; Classifying the second processing result based on the drug resistance gene function and annotation information, and annotating the corresponding biological function and source microbial information to obtain a third processing result; Performing similarity analysis on different drug-resistant gene family sequences in the third processing result, and performing processing based on the similarity analysis result to obtain target drug-resistant gene sequence information; Based on the target drug-resistant gene sequence information, a target drug-resistant gene database is generated, and the annotation information in the target drug-resistant gene database includes: gene name, gene family name, source database, drug-resistant gene type, drug-resistant mechanism, description information, species source information, whether SNP verification is required, SNP name, SNP mutation information and literature identification source information.

2. A drug resistance gene identification system, It is characterized in that include: An acquisition unit, used for acquiring a target sample to be detected; The acquisition unit includes: a first acquisition subunit, which is used to acquire the original sequencing sequence of the target to be detected; a quality control subunit, which is used to perform quality control on the original sequencing sequence to obtain the target sample to be detected, wherein the quality control at least includes filtering low-quality sequences, cutting off low-quality bases at both ends of the sequence, and removing plasmid sequences and host genome sequences that are not related to drug resistance genes; An analysis unit, configured to perform drug resistance analysis on the target sample to be detected based on a target drug resistance gene database to obtain an initial drug resistance analysis result, wherein the target drug resistance gene database includes homologous drug resistance gene sequences and single nucleotide polymorphism (SNP) drug resistance gene data; A correction unit, used to correct the initial drug resistance analysis result to obtain a target drug resistance detection result; the correction unit includes: a second acquisition subunit, used to obtain clinical data of a target object corresponding to the target sample to be detected; a third acquisition subunit, used to obtain target drug resistance monitoring data; a correction subunit, used to correct the initial drug resistance analysis result based on the clinical data of the target object and the target drug resistance monitoring data, to obtain a target drug resistance detection result; A database establishment unit, wherein the database establishment unit is specifically used for: Obtaining drug-resistant gene sequences from a multidimensional source database, wherein the drug-resistant gene sequences include homologous drug-resistant gene sequences and single nucleotide polymorphism (SNP) drug-resistant gene sequences; multidimensional sources refer to different sources; Integrating the drug-resistant gene sequences to remove redundant drug-resistant gene sequences and obtain a first processing result, wherein removing the drug-resistant gene sequences includes retaining a target base sequence; Classifying the first processing result according to the drug resistance gene family as a unit to obtain a second processing result; Classifying the second processing result based on the drug resistance gene function and annotation information, and annotating the corresponding biological function and source microbial information to obtain a third processing result; Performing similarity analysis on different drug-resistant gene family sequences in the third processing result, and performing processing based on the similarity analysis result to obtain target drug-resistant gene sequence information; Based on the target drug-resistant gene sequence information, a target drug-resistant gene database is generated, and the annotation information in the target drug-resistant gene database includes: gene name, gene family name, source database, drug-resistant gene type, drug-resistant mechanism, description information, species source information, whether SNP verification is required, SNP name, SNP mutation information and literature identification source information.

3. An electronic device, It is characterized in that include: Memory, used to store programs; A processor is used to execute the program, wherein the program is specifically used to implement the drug resistance gene identification method as claimed in claim 1.